Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 194.13
DARA's Cash to Debt is ranked higher than
54% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. DARA: 194.13 )
Ranked among companies with meaningful Cash to Debt only.
DARA' s Cash to Debt Range Over the Past 10 Years
Min: 0.16  Med: 355.63 Max: No Debt
Current: 194.13
Equity to Asset 0.64
DARA's Equity to Asset is ranked lower than
55% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. DARA: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
DARA' s Equity to Asset Range Over the Past 10 Years
Min: -0.14  Med: 0.76 Max: 0.96
Current: 0.64
-0.14
0.96
F-Score: 5
Z-Score: -10.35
M-Score: -1.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -288.17
DARA's Operating margin (%) is ranked lower than
64% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. DARA: -288.17 )
Ranked among companies with meaningful Operating margin (%) only.
DARA' s Operating margin (%) Range Over the Past 10 Years
Min: -17846.3  Med: -6928.93 Max: -498.15
Current: -288.17
-17846.3
-498.15
Net-margin (%) -287.49
DARA's Net-margin (%) is ranked lower than
65% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. DARA: -287.49 )
Ranked among companies with meaningful Net-margin (%) only.
DARA' s Net-margin (%) Range Over the Past 10 Years
Min: -14083.23  Med: -6689.07 Max: -477
Current: -287.49
-14083.23
-477
ROE (%) -89.94
DARA's ROE (%) is ranked lower than
79% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. DARA: -89.94 )
Ranked among companies with meaningful ROE (%) only.
DARA' s ROE (%) Range Over the Past 10 Years
Min: -259.57  Med: -136.96 Max: -20.16
Current: -89.94
-259.57
-20.16
ROA (%) -70.13
DARA's ROA (%) is ranked lower than
80% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. DARA: -70.13 )
Ranked among companies with meaningful ROA (%) only.
DARA' s ROA (%) Range Over the Past 10 Years
Min: -176.71  Med: -104.05 Max: -14.04
Current: -70.13
-176.71
-14.04
ROC (Joel Greenblatt) (%) -31118.90
DARA's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. DARA: -31118.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DARA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -24415.58  Med: -11889.58 Max: -4436.24
Current: -31118.9
-24415.58
-4436.24
EBITDA Growth (3Y)(%) -54.30
DARA's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. DARA: -54.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DARA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -48.50 Max: 9.3
Current: -54.3
0
9.3
EPS Growth (3Y)(%) -52.80
DARA's EPS Growth (3Y)(%) is ranked lower than
92% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. DARA: -52.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DARA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -52.50 Max: 7.3
Current: -52.8
0
7.3
» DARA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

DARA Guru Trades in Q1 2015

Jim Simons 144,900 sh (-27.89%)
» More
Q2 2015

DARA Guru Trades in Q2 2015

Jim Simons 316,240 sh (+118.25%)
» More
Q3 2015

DARA Guru Trades in Q3 2015

Jim Simons 309,700 sh (-2.07%)
» More
Q4 2015

DARA Guru Trades in Q4 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DARA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:BITRF, OTCPK:OBMP, NAS:RXII, NAS:CSBR, OTCPK:BNHLF, OTCPK:SARSF, NAS:JAGX, OTCBB:SNGX, OTCPK:ENDV, NAS:XTLB, OTCPK:DMCAF, OTCPK:ENZN, AMEX:BPMX, OTCPK:MBVX, OTCPK:QBIO, OTCPK:SDOI, NAS:CERC, NAS:BIOD, NAS:MATN, OTCPK:OPNT » details
Traded in other countries:PJUF.Germany,


DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
P/B 2.82
DARA's P/B is ranked higher than
56% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. DARA: 2.82 )
Ranked among companies with meaningful P/B only.
DARA' s P/B Range Over the Past 10 Years
Min: 0.02  Med: 0.96 Max: 8.07
Current: 2.82
0.02
8.07
P/S 4.92
DARA's P/S is ranked higher than
69% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. DARA: 4.92 )
Ranked among companies with meaningful P/S only.
DARA' s P/S Range Over the Past 10 Years
Min: 0.43  Med: 6.39 Max: 815.96
Current: 4.92
0.43
815.96
Current Ratio 1.81
DARA's Current Ratio is ranked lower than
78% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. DARA: 1.81 )
Ranked among companies with meaningful Current Ratio only.
DARA' s Current Ratio Range Over the Past 10 Years
Min: 0.69  Med: 5.12 Max: 25.68
Current: 1.81
0.69
25.68
Quick Ratio 1.73
DARA's Quick Ratio is ranked lower than
75% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. DARA: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
DARA' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 4.45 Max: 25.26
Current: 1.73
0.69
25.26
Days Inventory 102.06
DARA's Days Inventory is ranked higher than
59% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. DARA: 102.06 )
Ranked among companies with meaningful Days Inventory only.
DARA' s Days Inventory Range Over the Past 10 Years
Min: 152.01  Med: 190.83 Max: 950.52
Current: 102.06
152.01
950.52
Days Sales Outstanding 118.61
DARA's Days Sales Outstanding is ranked lower than
79% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. DARA: 118.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
DARA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.49  Med: 262.10 Max: 1169.35
Current: 118.61
2.49
1169.35
Days Payable 395.12
DARA's Days Payable is ranked higher than
90% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. DARA: 395.12 )
Ranked among companies with meaningful Days Payable only.
DARA' s Days Payable Range Over the Past 10 Years
Min: 397.96  Med: 1033.33 Max: 21033.13
Current: 395.12
397.96
21033.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.67
DARA's Price/Net Cash is ranked lower than
77% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. DARA: 14.67 )
Ranked among companies with meaningful Price/Net Cash only.
DARA' s Price/Net Cash Range Over the Past 10 Years
Min: 0.59  Med: 4.40 Max: 34.48
Current: 14.67
0.59
34.48
Price/Net Current Asset Value 6.29
DARA's Price/Net Current Asset Value is ranked lower than
57% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. DARA: 6.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DARA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.58  Med: 3.94 Max: 98.09
Current: 6.29
0.58
98.09
Price/Tangible Book 6.29
DARA's Price/Tangible Book is ranked lower than
65% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. DARA: 6.29 )
Ranked among companies with meaningful Price/Tangible Book only.
DARA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 3.92 Max: 50.56
Current: 6.29
0.56
50.56
Price/Median PS Value 0.77
DARA's Price/Median PS Value is ranked higher than
62% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. DARA: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
DARA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.75  Med: 12.91 Max: 724.31
Current: 0.77
0.75
724.31
Earnings Yield (Greenblatt) (%) -72.50
DARA's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. DARA: -72.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DARA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -72.5  Med: 1143.30 Max: 394814.8
Current: -72.5
-72.5
394814.8

More Statistics

Revenue (TTM) (Mil) $3.54
EPS (TTM) $ -0.52
Short Percentage of Float0.21%
52-Week Range $0.67 - 1.05
Shares Outstanding (Mil)19.76

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue (Mil $) 4 9 12 15
EPS ($) -0.56 -0.31 -0.19 -0.08
EPS w/o NRI ($) -0.56 -0.31 -0.19 -0.08
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for DARA

Headlines

Articles On GuruFocus.com
DARA Biosciences Inc. Reports Operating Results (10-Q) Aug 13 2010 
DARA Biosciences Inc. Reports Operating Results (10-Q) May 14 2010 
DARA Biosciences Inc. Reports Operating Results (10-Q) Nov 13 2009 
DARA Biosciences Inc. Reports Operating Results (10-Q) Aug 14 2009 
DARA Biosciences Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
DARA BIOSCIENCES, INC. Financials Dec 08 2015
MIDATECH PHARMA US INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Dec 04 2015
DARA BioSciences, Inc. Earnings Q3, 2015 Dec 03 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Dec 02 2015
DARA BioSciences Announces Stockholder Approval of Merger With Midatech Dec 02 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 18 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 02 2015
DARA BioSciences Announces Third Quarter 2015 Results Nov 02 2015
Edited Transcript of DARA earnings conference call or presentation 13-Aug-15 1:00pm GMT Oct 19 2015
DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015 Oct 06 2015
DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only... Oct 05 2015
DARA BioSciences, Inc. Earnings Q2, 2015 Oct 02 2015
DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29,... Sep 23 2015
DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on... Sep 02 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 12 2015
DARA BioSciences Announces Second Quarter 2015 Results Aug 12 2015
DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results Aug 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)